Lilly's Weight Loss Pipeline Beyond Zepbound: What the Ongoing Trials Measure and What They Still Can't Tell Us

The Lilly weight loss pipeline reaches well beyond tirzepatide. The company is testing other molecules and combinations that act through different biological routes, and several are in late-stage trials. Reading those studies takes more than memorizing drug names. This post explains what the ongoing trials measure, how to read each phase, and which questions they still can't answer.

Why Lilly tests combinations and new molecules

Tirzepatide acts on two receptors, GIP and GLP-1. Researchers want to know whether a third pathway can add to that effect, or cover cases where the existing pathways fall short. Retatrutide adds activity at the glucagon receptor, which is why it is described as a triple agonist. Other lines of research aim at different targets. Eloralintide is an amylin analog, bimagrumab is an antibody designed to help preserve muscle, and orforglipron is a small molecule taken by mouth.

Each candidate's mechanism should be checked in its ClinicalTrials.gov entry and in the original publication, since investigational molecules don't have a product label yet. For the approved drug, tirzepatide received FDA approval for chronic weight management in November 2023. Its status in Brazil should be confirmed directly with Anvisa, because regulatory decisions change over time.

The main programs in progress

Retatrutide is in phase 3 under the TRIUMPH series, which covers obesity and related conditions. Don't rely on a headline total for participants. Open the registry, find each study's exact name, and compare the enrollment number and primary outcome there. Orforglipron is also in phase 3, under the ATTAIN program, and its registry entries list the primary endpoints each study measures. Eloralintide is in phase 2, so study length and dosing details will come from the meeting abstract or the peer-reviewed paper. Bimagrumab combined with tirzepatide is a phase 2 study that asks whether lean mass can be kept while weight comes down.

Phases can change as a study moves forward, so confirm the current status on the registry on the day you read about it. If you've followed TirzeBlog since tirzepatide was still in trials, you already watched one molecule travel from early data to an approved medicine. That path helps explain why early numbers for these candidates deserve a slower read.

How to read the phase of a study

Phase 1 studies check safety and how the body handles the drug, usually in small groups. Phase 2 studies give the first real look at efficacy and dose, but they rarely include enough people to confirm a benefit. Phase 3 studies are large and often compare the candidate with placebo or an established treatment. They form the core of the evidence sent to regulators when a company asks for approval.

A phase 2 result is not an approval. Many candidates never reach pharmacies, for reasons that include weak results, safety signals, or business decisions. The strongest trials are randomized, double-blind, and placebo-controlled. Randomization sorts participants into groups by chance, so the groups start out similar. Double-blind means neither the volunteers nor the research team knows who receives the active drug. Placebo control gives one group an inactive treatment, which separates the drug's effect from expectations and from ordinary weight changes over time. The NIH explains these basics in plain language on its clinical trials pages.

Here's a practical check. Search the study's NCT number on ClinicalTrials.gov, then compare the registry entry with the published paper. Look at the primary outcome, planned timeline, and sample size. If any of them changed, find out why before trusting the final numbers.

What the trials actually measure

The most common primary outcome is the percent change in body weight at a set week, compared with placebo. Percentages travel better than absolute numbers. A loss of several kilograms means little without the starting weight, while a percentage shows the effect relative to each person's body.

Studies often report thresholds, such as losing at least 5, 10, 15, or 20 percent of body weight. Each threshold answers a different question, so compare them only within the same study. Not every trial reports every threshold, and a headline that cites only the top figure may hide the rest of the distribution. Secondary outcomes like waist circumference, blood pressure, HbA1c, and lipids add context, but check which ones were defined in advance rather than added after the results came in.

The analysis method changes the final figure too. A per-protocol analysis counts only people who followed the plan closely. An intention-to-treat analysis counts everyone originally assigned, including people who stopped early, and usually gives a more conservative picture. Check which one a headline uses before comparing numbers across articles. Copy every percentage directly from the original publication, never from memory or from press coverage.

What we still don't know

Durability is the biggest open question. Researchers still need to learn what happens to weight after treatment stops, and how long results last with maintenance dosing. Many studies answer only part of this, because their follow-up periods are limited.

Body composition matters just as much. A scale reading doesn't show how much of the loss came from fat and how much came from lean mass. The bimagrumab study is designed to test whether muscle is preserved, so look for the actual body composition data in the publication instead of relying on the claim alone.

Side effects need specifics. Check each publication for heart rate changes, gastrointestinal events, sensory symptoms, and discontinuations due to adverse events. Note the reported frequencies rather than a general statement that a drug is well tolerated. Populations matter too. Find out how many Brazilians, older adults, people with type 2 diabetes, and people across different BMI ranges were enrolled, because a result in one group may not carry over to another.

Direct head-to-head comparisons remain rare. Many new molecules are tested against placebo rather than against tirzepatide itself, which makes superiority claims hard to judge. Our blog follows these trials as they're published and flags when a comparison is direct or only indirect.

How to read headlines and press releases

Sources carry different weight. Company press releases announce topline results, often before peer review, and Lilly's news releases page is where those announcements appear. Conference abstracts and slides offer early detail but usually little methodology. Peer-reviewed articles include full methods and limitations, which is where firm conclusions belong.

Words like "superior," "better than," and "promising" need support. Claiming superiority requires the same outcome measured the same way, a comparable study length, a design that actually compares the drugs, and statistical significance on the key endpoint. "Promising" is a judgment about early data, not a result. Subgroup and exploratory analyses help generate hypotheses, but they can't prove that a drug works in a particular group.

Before you accept any headline, check who funded the study and whether the authors disclose ties to the sponsor. Then look at how many people were enrolled and how long they were followed. Finally, confirm that the main outcomes were defined before the study began. These checks take minutes and catch most of the overstatement that circulates online.

What this means if you're on treatment or thinking about starting

None of these candidate molecules is available as routine treatment in Brazil at the moment. Confirm the current status with Anvisa before assuming access to any of them.

Products sold as retatrutide or under similar names outside regulated channels may be counterfeit or made without quality control. This post won't point you to a seller, and it's wise to avoid anyone who does. Unverified products carry risks that no published study has evaluated.

If you're on tirzepatide or considering it, talk with your doctor about approved options, realistic goals, and how progress will be monitored. Good plans look beyond the scale to muscle strength, sleep, eating patterns, and daily activity. Structured follow-up with your clinician can help you tell real progress from noise. Readers who want the full picture can follow the studies at TirzeBlog, which gathers content on tirzepatide and ongoing research without the hype. Bring your questions to your care team and let the evidence set the pace.

FAQ

Is retatrutide approved for weight loss yet?

Not according to the public record at the time of writing. Check the FDA and Anvisa websites for updates before making any decision.

What does a phase 2 result actually tell me?

It gives an early signal about dose and effect in a limited group. It doesn't confirm benefit or safety at scale, and it doesn't guarantee approval.

Why do two articles report different percentages for the same drug?

They may use different analysis populations, time points, or comparators. Go back to the original publication and read the methods section.

Sources

• FDA approves new medication for chronic weight management (U.S. Food and Drug Administration)
• ClinicalTrials.gov: retatrutide studies (U.S. National Library of Medicine)
• ClinicalTrials.gov: orforglipron studies (U.S. National Library of Medicine)
• ClinicalTrials.gov: bimagrumab studies (U.S. National Library of Medicine)
• Basics of clinical trials (National Institutes of Health)
• Anvisa: medicamentos (Agência Nacional de Vigilância Sanitária)
• Eli Lilly and Company news releases